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Abstract
Background: Management of secretions in children with cerebral palsy is often problematic due to severe deformation
of the rib cage, impaired cough, and patients’inability to collaborate with chest physiotherapy. Assessing the effectiveness
of different methods and techniques of secretion clearance is hampered by the lack of direct outcome measures and by
limited patient cooperation.
This observational study was planned to evaluate the efficacy of Free Aspire, a device that utilizes a special method to
remove secretions from the bronchial tree in hypersecretive patients.
Case presentation: Cerebral palsy patients were selected who had experienced more than 3 episodes of
respiratory exacerbations in the latest year despite therapeutic optimization (including bronchial clearance
techniques) and who had received at least one antibiotic course or underwent at least one access to the
Emergency Room (ER) or admission to hospital in the 6 months prior to the study. Patients with congestive heart
failure or contraindications for Free Aspire were excluded. We prospectively enrolled 8 patients (mean age 8.25 ±
6.11 years) who had been using in the past techniques for clearance secretions different from Free Aspire.
The treatment with Free Aspire consisted of at least two 20-min sessions per day. The observational study period was
18 months.
In the 6 months prior to start the treatment (T0), patients had a mean number of 4.0 ± 2.23 visits from the primary care
pediatrician (PCP), spent 14 ± 20 days in hospital, and received antibiotics for 35 ± 17 days. After the first 6 months of
treatment (T1), they had 1.7 ± 0.73 PCP visits, no days spent in hospital, and 9.75 ± 10.4 days of antibiotic therapy. At
12 months of treatment (T2), PCP visits were 1.7 ± 0.70, days in hospital 1.12 ± 0.3, and days of antibiotics 10.25 ± 10. At
18 months of treatment (T3) no hospitalizations had occurred, PCP visits were 0.25 ± 0.70, and days of antibiotic
therapy 4.8 ± 12.62. The technique proved to be safe and well tolerated.
Conclusion: Our findings show that Free Aspire for bronchial secretion clearance in cerebral palsy patients with limited
capacity to collaborate is safe and effective in reducing the impact of respiratory exacerbations in terms of number of
PCP visits, days spent in hospital, and days of antibiotic therapy; its regular use maintains this effect in time.
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Background
Cerebral palsy (CP) is the most frequent cause of motor
handicap in children. The prevalence of CP is stable and it
is estimated to affect 2 to 3 per 1000 births in Europe [1].
The life expectancy for individuals affected by CP is gener-
ally lower that age-matched cohorts of healthy subjects, but
varies according to the severity of the motor and cognitive
handicap. European data suggest that CP is associated to
comorbidities such as severe mental retardation in 31 %,
epilepsy in 21 %, severely retarded development with inabil-
ity to walk in 20 %, and blindness in 11 % of cases [2, 3].
Children with severe neurological impairment have a
high incidence of different respiratory disturbances and.
respiratory failure is actually one of the most frequent
causes of death [4]. Baikie et al. studied 63 spastic tetra-
plegic children unable to walk, in order to document the
prevalence of pulmonary aspiration and the best method
for diagnosis, and found that 56 % underwent aspiration
causing infection [4, 5]. Reddihough et al. published a sur-
vey from the Infantile Cerebral Palsy registry in Victoria,
Australia: the majority of 155 children who died between
1970 and 1995 had had severe respiratory problems. Re-
spiratory symptoms were common in these patients, with
daily cough or wheezing in 58 %, cough during feeding at
least 1 day/week in 84 %, episodes of asthma in the previ-
ous 6 months in 34 %, and snoring in 44 % with apnea re-
corded in 10 %. Respiratory symptoms were present in
24 %, with cough when drinking milk found in 44 %; at
the physical examination rales were reported in 19 % and
wheezing in 17 % of patients [6].
Depending on the severity of the disorder, ineffective
cough and impaired removal of secretions, children with
CP can present early in life recurrent infections of the
airways, pneumonia, and atelectasis [7]. These can cause
airways obstruction and lung damage, and further impair
the respiratory mechanics, as well as the nutritional
status [8]. Children with CP can develop gas exchange
abnormalities (hypercapnia and hypoxemia) and sleep-
associated respiratory disturbances, similarly to patients
with neuromuscular diseases. Both conditions can develop
scoliosis due to the altered muscular tone [7, 8]. The re-
duced chest wall compliance and asimmetrical lung ex-
pansion aggravate the lung impairment. The deformity of
the spinal column can further reduce the capacity to
cough and the clearance of lung secretions [8]. Hence,
children with CP are susceptible to respiratory diseases for
several reasons: 1) a tendency to aspire food or liquid on
account of swallowing dysfunction, with or without gas-
troesophageal reflux; 2) a tendency to scoliosis, and rota-
tional deformities of the airways that lead to disventilation
of the lower lobes; 3) cough impairment; and 4) a ten-
dency to reduced nasopharyngeal muscle tone which leads
to upper airways obstruction and obstructive sleep apnea
syndrome.
While several methods exist that allow the management
of airways secretions in a comfortable, noninvasive mode,
these are nevertheless influenced by the patient’s cognitive
status and ability to cooperate [9–11]. An efficient drainage
of respiratory secretions through a “vacuum” effect has
been found to be effective and safe in patients with chronic
obstructive pulmonary disease (COPD) and neuromuscular
disorders [12, 13]. The effectiveness of such a treatment in
pediatric patients with CP is still under debate [11].
Free Aspire is a device for the non-invasive removal of
tracheobronchial secretions, developed for adult and
paediatric patients with reduced or no capacity to cough
and expectorate.
To determine whether Free Aspire is safe and well toler-
ated and can facilitate mucociliary clearance and thus, im-
prove respiratory health in the long term, we prospectively
studied pediatric patients with CP and severe lung impair-
ment due to retention of bronchial secretions.
Case presentation
Among subjects followed up at a respiratory outpatient
clinic for Rehabilitation of severe infant disabilities, pa-
tients with CP aged > 2 years, either male or female, were
consecutively enrolled for this study according to the fol-
lowing inclusion criteria:
1) diagnosis of CP by a qualified medical specialist;
2) absence of acute respiratory distress;
3) frequent episodes of respiratory exacerbations
(>3/year) despite optimized therapy and
bronchial clearance with devices different from
Free Aspire
4) at least one antibiotic course or one access to
ER or hospital admission in the 6 months
preceding the study.
Patients who had congestive heart failure or contrain-
dications for Free Aspire (i.e. neck lesions, incapacity to
maintain an upright position, facial deformities, and
hemodynamic instability) were excluded from the study.
Written informed consent to the treatment protocol
was obtained from the parents or legal tutors of the pa-
tients based on the guidelines of the Regional Healthcare
System of Emilia Romagna and the local healthcare ser-
vices of Reggio Emilia. With the start of the study, base-
line data were collected, including the history of
hospitalizations and antibiotics used for respiratory com-
plications during the previous 6 months (Table 1). The
project was approved by institutional review board.
Device and study procedure
Free-Aspire (MPR, Medical Products Research S.r.l, Italy) is
an electromedical machine for removing broncho-alveolar
secretions. The device utilizes Vakűm technology: during
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expiration the airflow is accelerated by the Venturi effect in-
side a special connector. The acceleration is activated only
during the expiratory phase, is proportional to the flow of
air on spontaneous breathing, and does not require any co-
operation. The secretions slide along the layer of liquid
lining the bronchial epithelium until they reach the glottis
from where they are either expctorated or swallowed. No
negative pressure is generated inside the airways, avoiding a
possible risk of collapse. Free Aspire does not assist, nor
does it cause cough; no respiratory effort is required for the
elimination of the secretions. Free Aspire can be used for
20 min without causing respiratory fatigue or discomfort.
The caregivers were asked to carry out the therapy for
20 min at least twice daily, for the duration of the study
period. A respiratory therapist instructed caregivers in
the procedure and monitored the first treatment session.
The participants were trained to perform the chest
physiotherapy using an oronasal mask, with supplemen-
tary sessions in case of persistent hypersecretion.
The observation period of this study lasted 18 months
from the start of treatment (T0) with Free Aspire. Evalu-
ation and data collection were carried out at 6 (T1), 12
(T2) and 18 (T3) months, respectively.
Clinical outcomes
The set of clinical outcome measures included the num-
ber of pediatrician visits, days spent in hospital and days
of antibiotic therapy for a respiratory exacerbation; the
occurrence of adverse events in the course of the study
were registered too.
Control data for comparison were represented by
historical data of the same patients as taken by elec-
tronic health files of the 6 months before the start of
the study.
Statistical analysis
Since this was a preliminary observational study, it was
not powered in terms of any measure identified as the
primary outcome. Results are shown as mean ± standard
deviation (SD) unless otherwise specified. The analysis
of within-group change from baseline to follow-up visits
was carried out for each outcome at the same time. The
continuous variables for the outcome measures were an-
alyzed using Student’s paired t-test. Values of p < 0.05
were considered as significant.
Patient demographic and clinical characteristics
Eight patients were enrolled, all male, with a mean age
of 8.25 ± 6.11 (SD) years.
The primary causes of CP were: prematurity (n = 3),
cerebral asphyxia (n = 2), and meningitis (n = 2); in 1
subject the cause was unknown. Patients were under
the care of a local Neuropsychiatry unit. Multidisciplin-
ary and multiprofessional assessments were carried out
by a team including a rehabilitation therapist, an occu-
pational therapist, a physiatrist and a neuropsychiatrist.
The diagnosis of CP was established through specialist
evaluations by pediatricians and pediatric neurologists,
as documented in our electronic datawarehouse for
healthcare data. All 8 patients had a diagnosis of global
cognitive retardation and impaired development, with
the need for full assistance in daily living activities. All
presented with spastic tetraparesis and encephalopathy,
and were unable to walk. None had undergone non-
invasive ventilation, nor had a device for cough mech-
anical assistance, but in the previous 6 months they
had all used a positive expiratory pressure (PEP) mask.
All 8 patients had a history of aspiration, as documented
either by a diagnosis of aspiration pneumonia or by an ab-
normal swallowing test. Four patients were fed orally since
the parents refused a gastrostomy. Three had documented
gastroesophageal reflux disease and were fed through a
gastrostomy tube. One had undergone fundoplication. All
were receiving medical treatment for gastroesophageal re-
flux. All 8 patients had moderate/severe scoliosis (>15°
Cobb angle). One had undergone spinal correction.
In the 6 months prior to the study, 6 of the 8 patients
had been hospitalized, and 6 had accessed the ER for re-
spiratory disturbances; 6 had required a pediatrician visit
in the previous 6 months on account of respiratory
symptoms. All subjects had been prescribed oral antibi-
otics for respiratory complications in the 6 months prior
to the start of the study (Table 1).
Table 1 Demographic and clinical characteristics of the study
population (n = 8)
Demographics





Clinical history N. patients
Hospitalized for pulmonary complications
(in previous 6 months)
6
ER admissions (in previous 6 months) 6
Primary care pediatrician home visits
(in previous 6 months)
6
Oral antibiotics for respiratory exacerbations




Previous/current home use of airways
clearance techniques
8
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Outcome measures
All participants completed the study and were included
in the final analysis. No adverse events were registered
during the course of the study, such as pain or distress
or difficulty in tolerating the therapy.
With respect to baseline a statistically significant reduc-
tion, was observed in the home visits of the primary care
pediatrician for respiratory exacerbations (Fig. 1): 4.01 ±
2.23 at T0 compared to 1.5 ± 0.92 at T1 (p = 0.0095), 1.75
± 3.05 at T2 (p = 0.01), and 0.25 ± 0.70 at T3 (p = 0.0096).
While the difference between T1 and T3 (p = 0.011) was
again significant, those between T1 and T2 (p = 0.81), T2
and T3 (p = 0.22) were not statistically important.
Regarding days spent in hospital (Fig. 2), in the 6 months
before the study the mean stay in hospital was 9.81 ±
10.55 days compared to zero days in the 6 months follow-
ing treatment; at 12 months (T2) the mean stay in hospital
was 0.75 ± 1.48 days, to become zero again at 18 months.
Comparing T0 with T1 the difference was significant (p =
0.02), as were T0 versus (vs) T2 (p = 0.05), and T0 vs T3
(p = 0.02). The differences T1 vs T2 (p = 0.19), T1 vs T3
(p = 0.9) and T2 vsT3 (p = 0.19) were not significant.
The use of antibiotics (Fig. 3) showed the same trend.
From a mean 35.14 ± 17.99 days of antibiotic treatment
in the 6 months prior to the study (T0), the use of anti-
biotics decreased to 9.75 ± 8.31 days in the following
6 months (T1); at T2 days of antibiotic use were 10.25
± 16.20, and at T3 4.8±12.62. Also in this case, the dif-
ference T0 vs T1 was significant (p =0.015), as were the
differences T0 vs T2 (p = 0.006), and T0 vs T3 (p =
0.04). The comparisons T1 vs T2 (p = 0.72), T1 vs T3
(p = 0.40), and T2 vs T3 (p = 0.44) were not statistically
significant.
Discussion
Cerebral palsy (CP) is the most frequent cause of motor
handicap observed in childhood and is frequently associ-
ated with respiratory problems such as ineffective cough,
pulmonary aspiration and sleep-disordered breathing.
An altered secretion clearance can lead to the develop-
ment of recurrent pulmonary infections, bronchiectasis
and, eventually, to respiratory failure. While in infantile
neuromuscular disorders there are many articles pub-
lished on the management of similar respiratory problems,
including the use of devices for chest physiotherapy, the
literature on CP is scant [14, 15]. Methods such as the
cough machine, PEP mask and chest vibrations are now
common in neuromuscular patients [16–18]. Among few
studies on chest physiotherapy in CP [19], Plioplys et al. in
2002 [20] investigated the routine use of high-frequency
chest wall compression (using the Vest system) in a pro-
spective non-controlled study in 7 children with CP (5 of
whom had a tracheostomy) resident in a specialized
pediatric care facility. The total number of pneumonia epi-
sodes and antibiotic courses diminished from 36 per year
before Vest to 18 during the year of treatment, and the
number of pneumonia-related hospitalizations decreased
from 9 to 3. Another study published by Yuan et al. [21]
shows that also high-frequency external vibrations were
able to reduce the number of hospital admissions in pa-
tients with CP and neuromuscular diseases compared to
controls. A recent Cochrane review analyzed the effi-
cacy of non-pharmacological treatments for respiratory
problems in children with severe retardation of global
development: 15 studies of relevance were identified.
The findings, even if related to heterogeneous treat-
ments, showed that there were potential benefits, and
Fig. 1 Home visits by the primary care pediatrician (PCP) for respiratory problems
Garuti et al. Italian Journal of Pediatrics  (2016) 42:7 Page 4 of 6
for most of the interventions no severe adverse events
were reported. The conclusion was that, irrespective of the
type of treatment, devices for the removal of secretions in
severe cerebral disability are potentially useful [22].
To date, no studies have been published evaluating
the use of Free Aspire in infantile CP or generally in
pediatric patients and, to our knowledge, this is the first
observational study on this particular patient group
treated with this device. The advantage of using the
Vakűm method is that the patient does not have to per-
form coordinated and stressful respiratory maneuvers.
The results of the study are extremely positive in terms
of major outcomes such as home visits of the primary
care pediatrician, days of hospitalization and use of antibi-
otics for respiratory exacerbations. The improvement was
particularly evident in the first 6 months of observation,
and persisted in the following 6 to 12 months. In the
18 months of clinical observation no patient abandoned
the treatment due to adverse events, such as pain or dis-
tress or difficulty in tolerating the therapy, therefore dem-
onstrating that the technique is well tolerated and safe.
A limitation of our study is the small patient sample:
despite our center represents a referral unit for pediatric
chest physiotherapy, we were able to recruit only a
group of 8 patients with cerebral palsy, all of whom,
however, completed the period of observation. A further
Fig. 2 Days spent in hospital for respiratory problems
Fig. 3 Days of antibiotic treatment
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weakness is represented by the longitudinal observa-
tional design and comparison with historical data of the
same patients, instead of a parallel group randomized
trial that would have required a larger number of sub-
jects. Anyway, patients had been on follow up at the
same center with the same health professionals and the
same approach for the two periods on comparison,
therefore the only variable was just the different instru-
mentation used for secretion removal.
Conclusion
From our findings, it can be concluded that the application
of Free Aspire to improve the bronchial secretion clearance
in non-collaborating patients with CP, is feasible and effect-
ive in reducing respiratory complications and exacerba-
tions, as well as the utilization of healthcare resources
(PCP visits, days of hospitalization, need for antibiotics).
Importantly, the regular use of the device maintains these
results in time. Further studies are necessary on how to
improve the mucociliary clearance and thus optimize the
respiratory condition of children with CP; to this end, ran-
domized controlled studies in larger patient cohorts are
required.
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